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SUPPLEMENT ARTICLE
Transgender People and HIV Prevention: What We Know
and What We Need to Know, a Call to Action
Kenneth H. Mayer, MD,* Beatriz Grinsztejn, MD, PhD,† and Wafaa M. El-Sadr, MD, MPH, MPA‡
Abstract: Transgender people have been disproportionally affected
by HIV, particularly transgender women. Their increased vulnera-
bility to HIV is due to multiple issues, including biological (eg,
increased efﬁciency of HIV transmission through receptive anal sex),
epidemiological (eg, increased likelihood of having HIV-infected
partners), structural (eg, social stigma limiting employment options),
and individual factors (eg, internalized stigma leading to depression
and substance use and risk-taking behaviors). There have been
limited culturally appropriate HIV prevention interventions for
transgender people, with many key prevention studies (eg, the iPrEx
PrEP study) enrolling transgender women in a study focusing on
men who have sex with men. This has resulted in limited
understanding of the optimal ways to decrease transgender people’s
risk for HIV acquisition. The current supplement of JAIDS is
designed to review what is known about HIV prevention for
transgender people and to highlight new insights and best practices.
The study reviews recent epidemiologic data, the pharmacology of
HIV prophylactic agents in individuals who may be using exogenous
hormones, and several recent multi-component interventions de-
signed to address the lived experience of transgender people.
Additionally, the study reviews the work going on at the NIH to
address transgender health in general and HIV prevention in speciﬁc,
as well as two important papers related to clinical trial design issues
and the ethical conduct of research in this frequently disenfranchised
population. It is the hope of the HIV Prevention Trials Network
(HPTN) that this supplement will promote new knowledge around
transgender health and the requisite issues that need to be addressed
in order to conduct optimal clinical trials. The ultimate hope is that
the information distilled in this supplement will inform investigators,
clinicians, and public health ofﬁcials in order to design further
research to develop optimal prevention interventions for transgender
people and to implement these interventions in ways that are
culturally congruent and health promoting.
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Since the earliest days of the AIDS epidemic, it has beenrecognized that transgender women have had dispropor-
tionate rates of HIV infections and AIDS-related mortality.1
Transgender women and men constitute less than 1 percent of
the general population in the US, but in many epidemiologic
studies, HIV prevalence has been in the double digits for
transgender women, with wide variations depending on how
the population was recruited.2,3 Much less is known about
transgender men and HIV, but several studies have docu-
mented that a signiﬁcant number may identify as “gay,”
and/or engage in sexual and drug-using behaviors that
increase their risk for HIV acquisition.4,5 Thus, one of the
early challenges to adequately understand the dynamics of
HIV transmission for transgender people has been their
relatively low representation in the general population, but
distinctively increased burden of HIV disease.
Individual factors that potentiate the HIV epidemic in
transgender women include engaging in receptive anal inter-
course6 and a high likelihood of having partners who may be are
at increased risk for HIV.7 Internalized transphobic stigma may
result in depression and substance use, which also potentiate
HIV risk taking.8–10 For many years, epidemiologic studies did
not distinguish transgender women from cisgender men who
have sex with men in the composite acronym “MSM,” because
they were perceived to have common risk for HIV acquisition
through anal sex, complicating optimal understanding of the
epidemiology of HIV among transgender individuals, and their
speciﬁc HIV prevention needs. This has been a disservice to
transgender women, in particular, because the social and
structural factors that increase the susceptibility of transgender
women to HIV differ substantially from those of cisgender men
who have sex with men. For example, in many cultures,
transgender individuals are recognized as having a distinct
gender minority status, eg, hijra in India and katoy in Thailand,
as well as 2-spirit individuals in Native American popula-
tions11–13 However, this recognition as a distinct social
grouping has also been associated with unique manifestations
of stigma, including challenges to maintaining an adequate
livelihood, resulting in poverty.14 Thus in many settings,
transgender individuals have been forced to rely on sex work
to survive, further exacerbating their risk for HIV.7 In
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addition, the category “MSM” has often not included trans-
gender men who have sex with men, stymying knowledge of
HIV risks in this potentially at-risk group.
To address the conundrum of developing culturally
tailored programs that are effective in decreasing HIV inci-
dence for transgender individuals, the ﬁrst fundamental is
having an appropriate understanding of the epidemiology of
behaviors and risks with speciﬁc types of partners in the diverse
cultures where transgender people live. However, the social
convention of referring to “transgender people” is problematic
since identity, behavior, and risk do not necessarily map in
a uniform manner. For example, epidemiologic studies suggest
that some transgender women are at particularly high risk for
HIV because of anal intercourse and sex work.2,11,14 But, many
of the studies to date that inform these presumptions have
recruited potential participants for the purpose of HIV pre-
vention research, which could lead to inherent biases due to
sampling (ie, only recruiting in risky venues). For transgender
men, the literature is limited with some studies suggesting
lower HIV risks, whereas other studies have suggested elevated
risk compared with cisgender men in the same communities.4,15
Some transgender men who are assigned a female sex at birth
may subsequently identify as “gay” and therefore also engage
in anal intercourse, as well as frontal/vaginal intercourse if
preoperative, and be at risk for HIV.4,8,15,16 It is extremely
important that in the design of prevention programs or research
for transgender people, there is an appreciation of the
heterogeneity of transgender people, and that interventions
are culturally tailored to the needs of speciﬁc communities.
Over the past decade, there has been an increased
awareness that the appropriate use of antiretroviral drugs can
be highly effective in decreasing HIV transmission globally.17
Early initiation of antiretroviral therapy is not only beneﬁcial
to the health of people living with HIV but can signiﬁcantly
reduce the risk of HIV transmission.18 Multiple studies have
also indicated that the use of pre-exposure prophylaxis (PrEP)
by HIV-uninfected individuals can signiﬁcantly decrease HIV
acquisition.19 However, to date, the beneﬁts of these impor-
tant prevention approaches have not been manifested among
transgender women and men in many parts of the world.
Because of high levels of social stigma and often structural
violence, transgender people have not been able to avail
themselves of available testing, prevention, care, and treat-
ment services.20,21 In addition, the use of PrEP presumes that
individuals are comfortable with discussing their sexual
behaviors with health providers, in settings where health care
system transphobia is common.22,23 The only PrEP study that
recruited a sufﬁcient number of transgender women was the
iPrEx study, in which there was no beneﬁt found for
transgender women using prophylactic medication, likely
due to small number of such participants.24 But, through
careful analysis of the 21 transgender women who became
HIV-infected among those who participated in iPrEx, it was
evident that these transgender women were not adherent to
study medication because none of them had detectible drug in
the blood at the time of infection.25
Future PrEP and treatment as prevention studies for
transgender women should address the factors that may lead
to suboptimal adherence in this population, including, where
possible, the need to provide comprehensive medical and
primary care services that integrate hormonal and surgical care
with antiretroviral management, and address individual issues,
such as depression, substance use, economic, and housing
instability, and the structural drivers of these syndemic
conditions. Where “one-stop” care is not feasible, it is
incumbent on local clinicians and programs to identify
appropriate referrals and to optimize the local standard of care.
Questions remain as to whether the supraphysiologic doses of
hormones that transgender people may use to medically afﬁrm
their sex could be interacting with antiretroviral medication and
attenuating the beneﬁts of PrEP.26–28 There are no data at
present to suggest that high doses of feminizing or masculin-
izing hormones would negate the beneﬁt of daily oral tenofovir
and emtricitabine for PrEP, but this area has not been
sufﬁciently studied and new work is underway to fully address
the issue of whether hormonal medication could interact with
medications used for PrEP. In addition, it is critical that every
effort be made to establish comprehensive services that meet the
unique needs of this population, including availability of
responsive and sensitive providers. Involvement of transgender
individuals in the design of such services and research efforts is
fundamental to their success.
This Journal supplement has been developed to provide
information on the state of the HIV epidemic among trans-
gender individuals and to inform the way forward in responding
to this public health challenge. The supplement builds on
a workshop sponsored by the HIV Prevention Trials Network
in June, 2015. In the ﬁrst article, Dr. Tonia Poteat et al29
review the global epidemiology of HIV and syndemic con-
ditions among transgender individuals. Dr. Peter Anderson
et al30 discuss available information about the interaction
between exogenous hormones and antiretroviral drugs. The
article contributed by Dr. Robert Grant et al31 delineates
what has been learned from the iPrEx study about trans-
gender women’s participation in one of the ﬁrst PrEP studies
and discusses new directions for further research in this area.
Dr. Sari Reisner et al32 discuss a holistic framework for
understanding the optimal health needs of transgender
people so that they can avoid HIV acquisition, and that if
they become infected, how they can live healthy and
productive lives. Dr. Robert Garofalo et al33 discuss
behavioral interventions that are evidence based and are
socially congruent for transgender women to optimize HIV
protection. Dr. Rona Siskind et al,34 who coordinated
a trans-NIH working group on sexual and gender minority
issues, discuss the efforts underway at the NIH to ensure that
ongoing and future clinical trials are sensitive to the realities
of the people being studied. Dr. Jim Hughes et al35
discusses statistical considerations in the evaluation of
HIV prevention interventions in populations that are not
highly represented in the general population but whose risk
for HIV acquisition and transmission is high. Last but
certainly not least, Dr. Jerome Singh et al36 discusses the
ethical considerations for conducting research among trans-
gender individuals given frequently coprevalent societal
stigma and structural violence.
The intent of this supplement is to frame the issues of
importance in developing a more holistic approach to the
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development of HIV prevention interventions for transgender
individuals. To conduct optimal research, many of the
underlying social and structural issues need to be addressed.
Transgender individuals need to achieve civic equality in all
societies so that they will be comfortable disclosing their
status and participating in research in an environment that
they feel is just and beneﬁcent. Their involvement in the
design of research studies and programs is fundamental. In
addition, resources need to be available to allow transgender
individuals to achieve their full potential and not to have to
rely on transactional behaviors for survival in an adversarial
environment. Thus, although this special issue is focused on
issues that may inform the conduct of future research, it is
also a clarion call for social justice for transgender individuals
so they can be fully empowered members of their societies
and avail themselves of the beneﬁts of the new advances in
HIV prevention and care.
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